According to Nipro’s president Yoshihiko Sano during a financial results briefing, Nipro has entered into a license agreement with Sapporo Medical University and develops autologous bone marrow-derived mesenchymal stem cells (MSC) for the treatment of cerebral infarction and spinal cord injury. The company will apply for approval in 2017 including manufacturing capacities.

Nikkei Biotech news release, May 19, 2017